Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.52 USD | -.--% | -3.08% | -40.14% |
04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
04-25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.14% | 564M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac Says Ongoing Phase 1 Clinical Programs for COVID-19, Flu Vaccines Show Positive Data in Adult Groups